The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > September 17, 2025
Daily News
September 17, 2025
- J&J’s Subcutaneous Rybrevant Faces Delay in Japan Approval Process
September 17, 2025
- Alnylam Sees Japan Business Doubling as Amvuttra Expands into ATTR-CM
September 17, 2025
- JPMA to Broaden Base of Biopharma Talent through On-Site Training: Committee Chair
September 17, 2025
- Kyorin/aTyr’s Efzofitimod Misses Primary Goal in Global PIII Trial
September 17, 2025
- Mitsubishi, J&J to End Stelara Co-Promotion in Japan at Year-End
September 17, 2025
- ASKA Presses Dalton Again for Stake Plan Details after Public Statement
September 17, 2025
- Japan Confirms First Case of Mpox Clade 1b
September 17, 2025
- Daiichi Bags FDA Breakthrough Therapy Status for Anti-CDH6 ADC
September 17, 2025
- MHLW Withdraws Sakigake Tag for Takeda’s TAK-925
September 17, 2025
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…